1. Home
  2. ACON vs ZVSA Comparison

ACON vs ZVSA Comparison

Compare ACON & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACON
  • ZVSA
  • Stock Information
  • Founded
  • ACON 2008
  • ZVSA 2014
  • Country
  • ACON United States
  • ZVSA United States
  • Employees
  • ACON N/A
  • ZVSA N/A
  • Industry
  • ACON Retail: Computer Software & Peripheral Equipment
  • ZVSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACON Technology
  • ZVSA Health Care
  • Exchange
  • ACON Nasdaq
  • ZVSA Nasdaq
  • Market Cap
  • ACON 4.8M
  • ZVSA N/A
  • IPO Year
  • ACON 2022
  • ZVSA N/A
  • Fundamental
  • Price
  • ACON $7.51
  • ZVSA $0.70
  • Analyst Decision
  • ACON Buy
  • ZVSA
  • Analyst Count
  • ACON 2
  • ZVSA 0
  • Target Price
  • ACON $481.00
  • ZVSA N/A
  • AVG Volume (30 Days)
  • ACON 74.1K
  • ZVSA 6.5M
  • Earning Date
  • ACON 04-09-2025
  • ZVSA 05-14-2025
  • Dividend Yield
  • ACON N/A
  • ZVSA N/A
  • EPS Growth
  • ACON N/A
  • ZVSA N/A
  • EPS
  • ACON N/A
  • ZVSA N/A
  • Revenue
  • ACON $45,724.00
  • ZVSA N/A
  • Revenue This Year
  • ACON $212.31
  • ZVSA N/A
  • Revenue Next Year
  • ACON N/A
  • ZVSA N/A
  • P/E Ratio
  • ACON N/A
  • ZVSA N/A
  • Revenue Growth
  • ACON N/A
  • ZVSA N/A
  • 52 Week Low
  • ACON $7.26
  • ZVSA $0.55
  • 52 Week High
  • ACON $3,500.42
  • ZVSA $6.70
  • Technical
  • Relative Strength Index (RSI)
  • ACON 33.37
  • ZVSA 45.85
  • Support Level
  • ACON $7.26
  • ZVSA $0.61
  • Resistance Level
  • ACON $8.30
  • ZVSA $0.79
  • Average True Range (ATR)
  • ACON 1.14
  • ZVSA 0.26
  • MACD
  • ACON 6.04
  • ZVSA 0.00
  • Stochastic Oscillator
  • ACON 7.68
  • ZVSA 10.73

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Share on Social Networks: